https://www.zonebourse.com/cours/action/SEAGEN-INC-10808/actualite/Seagen-Inc-annonce-que-TUKYSA-tucatinib-en-association-avec-le-trastuzumab-a-obtenu-une-revue-41815467/?utm_source=telegram&utm_medium=social&utm_campaign=share